Stryker account plan
Medical technology innovation
At a glance
Stryker is a global medical technology company in MedSurg, Neurotechnology and Orthopaedics, with FY2025 net sales of $25,116 million and ~56,000 employees.
Stryker is a global medical technology group offering surgical equipment and navigation, endoscopy, patient handling and emergency care, stroke and venous thromboembolism devices, joint replacement and trauma implants, and Mako robotic-arm assisted surgery. It sells in approximately 61 countries, mostly directly to doctors, hospitals and other healthcare facilities. FY2025 net sales were $25,116 million (+11.2% reported), with net earnings of $3,246 million and the United States accounting for $19,006 million of sales. It had approximately 56,000 employees at 31 December 2025.
Business units
MedSurg and Neurotechnology
62% of FY2025 net sales ($15,647 million)Instruments (now including Neuro Cranial), Endoscopy, Medical (patient handling, emergency care, Vocera clinical communication) and Vascular, renamed after the Inari acquisition. Sales grew 15.7% in 2025 at a 29.9% segment operating margin. Led by J. Andrew Pierce, Group President.
Orthopaedics
38% of FY2025 net sales ($9,469 million)Knees, Hips, Trauma and Extremities and, from 2026, Ortho Tech, which groups Mako, power tools and orthopaedic instruments. Mako SmartRobotics has performed more than two million robotic procedures; Spinal Implants was sold in April 2025. Led by Dylan B. Crotty, Group President.
Strategic priorities
- Growth at the high end of MedTech
- Stryker aims for sales growth at the high end of MedTech; 2026 guidance is 8.3%-9.3% organic sales growth and adjusted EPS of $14.95-$15.10.
- Acquisitions first
- Capital allocation prioritises acquisitions, then dividends, then buybacks; 2025 acquisitions cost $4,960 million, chiefly Inari, and AVS was bought in May 2026.
- Robotics leadership
- Mako 4, Mako Shoulder, Mako Total Hip revision and the Mako RPS handheld robot drive orthopaedics, where Stryker expects to outgrow the market by 200 to 300 basis points.
- Margin expansion
- The CFO remains committed to 150 basis points of operating margin expansion over 3 years.
- Connected hospital and SmartCare
- A new SmartCare unit combines Vocera and care.ai with beds in a Smart Hospital launch, alongside Connected OR integration.
Latest results
In Q2 2026 Stryker's net sales were $6,589 million, up 9.4% reported and 9.0% organic, with MedSurg and Neurotechnology at $3,625 million and Orthopaedics at $2,964 million. Adjusted EPS rose 17.9% to $3.69 and the adjusted operating margin rose 170 bps to 27.4%, helped by a reversal of 2025 tariffs. Six-month sales rose 6.1% to $12,609 million, a gap that reflects a cyber incident in Q1 2026 that halted production for almost 3 weeks. Stryker narrowed 2026 guidance to 8.3%-9.3% organic growth and adjusted EPS of $14.95-$15.10.
Investments and deals
- Inari acquisition
- Bought in February 2025 for $4,810 million net of cash, adding minimally invasive venous thromboembolism products to a new Peripheral Vascular business.
- AVS acquisition
- In May 2026 Stryker bought AVS, developing intravascular lithotripsy for peripheral arterial disease, for $435 million net cash plus up to $400 million in milestones.
- Spinal Implants divestment
- The Spinal Implants business was sold to Viscogliosi Brothers, LLC in April 2025.
- Capex
- Capex was $761 million in 2025 and $368 million in H1 2026.
- Share buybacks
- Stryker plans to resume buybacks in H2 2026, with $1,033 million of authorisation remaining.
Challenges and risks
- Cyber incident recovery
- A cyber incident first reported on 11 March 2026 caused "a global disruption to our business operations"; Stryker could not make product for almost 3 weeks.
- Peripheral vascular supply disruption
- A disruption at one Inari plant created a backorder with lost sales; US Vascular sales fell 6.7% in Q2 2026.
- Tariffs, inflation and supply chain
- Sole-source suppliers, US tariffs and inflation are named risks, along with oil and raw-material costs.
- Pricing pressure
- China's volume-based procurement, reimbursement changes and hospital consolidation create buyers with more bargaining power.
- IT and regulatory change
- Risks include the implementation of a new commercial global ERP system and EU MDR transition deadlines from May 2026 to December 2028.
What leadership says
“We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter.”
“All we have to do is make the products, and ship the products.”
“we love our position as market leaders in robotics”
“The Board and I have worked closely on a succession plan, and with our strong foundation in place, now is the right time for this leadership transition.”
Where a supplier can help
- Cybersecurity and IT resilience
- After a cyber incident that wiped 40,000 laptops and halted production, and with a new global ERP rollout under way, security, backup and IT operations vendors address a named challenge.
- Manufacturing and supply chain capacity
- Elevated capital backlog, a peripheral vascular plant disruption and sole-source supplier risk point to demand for manufacturing, quality and supply chain partners.
- M&A integration support
- With acquisitions as the first capital priority and Inari integration described as challenging, integration and commercial onboarding services fit the acquisition priority.
- Ambulatory surgery center build-out
- Hip and knee procedures in ASCs are pushing 20 percent and the Mako RPS targets ASCs; construction, equipment and IT partners can support that robotics growth priority.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Stryker?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Stryker Form 10-K for fiscal year 2025
- Stryker is a global medical technology group (MedSurg, Neurotechnology and Orthopaedics) selling in approximately 61 countries, mostly directly to doctors, hospitals and other healthcare facilities; it says it impacts more than 150 million patients a year and had approximately 56,000 employees at 31 December 2025 (approximately 28,000 in the US).
- FY2025 net sales were $25,116 million, up 11.2% reported and 10.7% in constant currency; excluding acquisitions and divestitures sales grew 10.3% in constant currency, driven by 9.9% unit volume and 0.4% price.
- Two segments: MedSurg and Neurotechnology $15,647 million (62% of sales, +15.7%) and Orthopaedics $9,469 million (38%, +4.3% reported, held back by the sale of Spinal Implants). The United States is $19,006 million of sales; international $6,110 million.
- Net earnings $3,246 million ($8.40 per diluted share); adjusted net earnings $5,267 million and adjusted EPS $13.63 (+11.8%). Operating margin 19.5%; segment operating margins 29.9% (MedSurg and Neurotechnology) and 29.8% (Orthopaedics).
- The stated goal is sales growth at the high end of MedTech, with capital allocation prioritising (1) acquisitions, (2) dividends, (3) share repurchases. 2025 acquisitions cost $4,960 million, chiefly Inari ($4,810 million, venous thromboembolism), which turned Neurovascular into a Vascular business; the Spinal Implants business was sold in April 2025.
- Mako SmartRobotics is available in more than 45 countries with more than two million robotic procedures performed; 2025 brought the Mako 4 platform, Mako Total Hip revision and Mako Shoulder (full US launch planned Q1 2026).
- Cash from operations $5,044 million; dividends $1,284 million ($3.36 per share); capex $761 million; $15,973 million of debt repayments scheduled, $1,000 million of it in 2026.
- Main risks: supply chain and sole-source suppliers, tariffs and inflation, pricing pressure (e.g. China volume-based procurement, hospital consolidation), competition including robotics and AI, acquisition integration, cyber and IT failures, the new commercial ERP rollout, EU MDR, product liability and a $754 million German tax assessment.
- Stryker reports second quarter 2026 operating results (earnings release)
- Q2 2026 net sales were $6,589 million, up 9.4% reported and 9.0% organic; MedSurg and Neurotechnology $3,625 million (+9.2% organic), Orthopaedics $2,964 million (+8.6% organic).
- Reported EPS rose 44.1% to $3.30 and adjusted EPS rose 17.9% to $3.69; adjusted operating margin rose 170 bps to 27.4% (reported 25.2%).
- The quarter included a $158 million "reversal of 2025 tariffs" in gross profit, which Stryker removed from adjusted results; reported gross margin was 68.3%, adjusted 66.0%.
- Kevin Lobo described "significant progress in our recovery from the cyber incident" first reported on 11 March 2026, and said the company enters H2 "with regained momentum".
- 2026 guidance narrowed to 8.3%-9.3% organic sales growth and adjusted EPS of $14.95-$15.10, with modestly positive pricing.
- Strongest US growth: Medical +12.6%, Trauma and Extremities +12.5%, Endoscopy +10.2%; Vascular fell 6.7% in the US. International sales grew 11.0% reported.
- A new Ortho Tech business (Mako, enabling technologies, orthopaedic instruments) is now reported in Orthopaedics, and Neuro Cranial sits inside Instruments.
- Stryker Form 10-Q for the quarter ended 30 June 2026
- H1 2026 net sales $12,609 million (+6.1% reported, +5.8% organic); Q2 $6,589 million (+9.4%, +9.0% organic). H1 adjusted EPS $6.29 (+5.4%), Q2 adjusted EPS $3.69 (+17.9%).
- H1 gross margin rose to 65.9% from 63.8%, mainly from a reduction of certain import tariffs (+130 bps), partly offset by idle production time caused by the Q1 2026 cybersecurity incident.
- New organisation from Q1 2026: an Ortho Tech business (Mako, power tools, cutting accessories, enabling technologies, orthopaedic instruments) moved into Orthopaedics, with $518 million of goodwill reallocated; Neuro Cranial now sits in Instruments.
- In May 2026 Stryker bought AVS, which is developing intravascular lithotripsy for peripheral arterial disease: $435 million net cash plus up to $400 million in milestones. AVS joins Peripheral Vascular alongside Inari.
- Q2 segment operating margins: MedSurg and Neurotechnology 28.1% (25.6% a year earlier), Orthopaedics 34.0% (33.1%).
- Operating cash flow was $1,842 million for H1; $1,000 million of notes were repaid. No shares were bought back in H1, with $1,033 million of authorisation left.
- Stryker announces leadership succession: Spencer Stiles to become CEO, Kevin Lobo Executive Chair (Form 8-K and press release)
- On 6 October 2026 Stryker announced that Kevin A. Lobo will step down as CEO on 31 December 2026 and become Executive Chair of the Board from 1 January 2027.
- Spencer S. Stiles, President and COO since January 2026, becomes CEO on 1 January 2027 and joins the Board, which grows from 10 to 11 seats.
- Stiles, 50, has spent 27 years at Stryker. He joined Endoscopy in 1999, was Group President, Orthopaedics from 2019 (Joint Replacement, Trauma and Extremities, Digital, Robotics and Enabling Technologies), and was also responsible for international regions and enterprise M&A strategy.
- He led the Wright Medical acquisition and the separation of the spinal implants business.
- Under Lobo (CEO since October 2012), annual net sales tripled from $8.7 billion in 2012 to more than $26 billion in 2026, across more than 60 acquisitions including Mako.
- Stiles's pay as CEO: $1,320,000 base salary, a bonus target of 150% of salary, and a proposed February 2027 long-term award worth $14,200,000 (40% options, 60% PSUs).
- Lead Independent Director Sheri McCoy called it "the culmination of a comprehensive, long-term succession planning process"; Stiles said he will continue executing the strategy.
- Stryker Q2 2026 earnings call (transcript)
- Q2 organic growth was 9%, high single digits in both segments, against a double-digit prior-year comparable; adjusted EPS rose 17.9% with help from tariff refunds. Lobo said Stryker exited Q2 "with regained momentum" after the cyber incident.
- A supply disruption at one plant in the Inari peripheral vascular business caused "a meaningful backorder situation with lost sales"; Lobo expects backorders to reach a manageable level by the end of Q3. The CFO agreed with an analyst's 50 to 75 basis point drag estimate as "in the ballpark".
- Capital demand is strong: elevated backlog, "zero cancellations", a record month of Mako sales and the best ever Q2 for Mako installations. The second half depends on how fast production ramps; plants have run consistently since 1 April.
- 2026 guidance narrowed to 8.3%-9.3% organic growth and $14.95-$15.10 adjusted EPS; the low end was raised from 8%. The CFO still commits to 150 basis points of operating margin expansion over 3 years.
- Capital allocation: M&A remains the number 1 priority, but Stryker will resume share buybacks in the second half (about a billion dollars authorised), citing cash generation and lower medtech valuations.
- Growth themes: Mako RPS handheld robot in full US launch, aimed first at competitors' surgeons and ASCs; hip and knee procedures in ASCs are "pushing 20 percent" against 5% before COVID; the new SmartCare unit (Vocera, care.ai) has strong orders.
- Peripheral vascular: the AVS lithotripsy device could be on sale before year end, and the PEERLESS II trial (1.2 thousand patients) reads out mid-next year. Lobo: "We will get back to the double digit growth".
- Stryker Q1 2026 earnings call (transcript)
- A cyber incident late in Q1 2026 caused "a global disruption to our business operations". Stryker could not make product for almost 3 weeks, Lobo spoke of 40,000 laptops wiped, and manufacturing was fully operational again the week of 1 April.
- Q1 organic growth fell to 2.4% (US 1.9%, international 3.9%); adjusted EPS of $2.60 was down 8.5%; adjusted gross margin 63.6% (-190 bps) and adjusted operating margin 21.1% (-180 bps), from lost absorption and tariffs.
- Full-year 2026 guidance was held at 8%-9.5% organic growth and $14.90-$15.10 adjusted EPS. Management expected revenue recognition to catch up in Q2 and deferred procedures and made-to-order capital to come back in H2.
- Lobo said there was no pause in orders and no lost customers, only some urgent cases; customers rated Stryker's response highly, and all backups worked.
- New Ortho Tech business (Mako, enabling technologies, orthopaedic instruments) and a new SmartCare business unit (Vocera plus care.ai, Smart Hospital launch).
- M&A: Amplitude Vascular Systems (IVL) agreed, as a step toward the broader cardiovascular space. Gross debt to EBITDA is 2.1, leaving "firepower"; soft-tissue robotics is being evaluated as an adjacency.
- Orthopaedics: Stryker expects to outgrow the market by 200 to 300 basis points, with Mako 4, Mako Shoulder, Mako RPS and Triathlon Gold. International growth is led by Japan (its second-largest country) and the Pangea launch in Europe.
Questions about Stryker
What does Stryker do?
Stryker makes medical technology across MedSurg, Neurotechnology and Orthopaedics, including surgical equipment, endoscopy, patient handling, stroke and vascular devices, joint implants and Mako surgical robots.
What is Stryker's revenue?
FY2025 net sales were $25,116 million, up 11.2% reported; Q2 2026 net sales were $6,589 million.
How many employees does Stryker have?
Stryker had approximately 56,000 employees at 31 December 2025, approximately 28,000 of them in the US.
Who leads Stryker?
Kevin A. Lobo is Chair and CEO through 31 December 2026; Spencer S. Stiles, President and COO, becomes CEO on 1 January 2027, with Lobo as Executive Chair.
What is Stryker's strategy?
Stryker targets growth at the high end of MedTech, funded first by acquisitions, with robotics, vascular and connected-hospital products as main platforms.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)